Core Insights - Swedish Orphan Biovitrum AB (Sobi) has entered into an acquisition agreement with Arthrosi Therapeutics, Inc. for a total transaction value of up to US$1.5 billion, including an upfront payment of US$950 million and contingent consideration of up to US$550 million, expected to close in the first half of 2026 [1][3]. Company Overview - Arthrosi Therapeutics, Inc. is a late-stage biotechnology company focused on developing pozdeutinurad, a next-generation URAT1 inhibitor aimed at managing gout and tophaceous gout [3][6]. - Sobi is a global biopharma company with approximately 1,900 employees and reported revenue of SEK 26 billion in 2024, dedicated to transforming the lives of individuals with rare diseases [7][8]. Strategic Implications - The acquisition enhances Sobi's gout franchise by adding pozdeutinurad, which is currently in two global Phase 3 clinical studies expected to read out in 2026, potentially becoming a preferred therapy for patients inadequately treated with first-line therapies [3][4]. - The collaboration is anticipated to accelerate growth for Sobi until the mid-2030s and beyond, reflecting a commitment to advancing treatment options for gout patients [4][5]. Financial Impact - Viva Biotech expects the merger to yield an aggregate gain of approximately US$40 million, contingent on regulatory and performance milestones [2].

每经AI快讯，维亚生物(01873.HK)涨超13%，截至发稿涨13.4%，报2.2港元，成交额481.54万港元。 （文章来源：每日经济新闻） ...

Core Viewpoint - Via Biotech (01873) shares rose over 13% following the announcement of a significant acquisition deal between Swedish Orphan Biovitrum AB (Sobi) and Arthrosi, in which Via Biotech is involved [1] Group 1: Acquisition Details - Sobi announced an acquisition agreement with Arthrosi, with a total transaction value of up to $1.5 billion, which includes an upfront payment of $950 million and up to $550 million in regulatory and commercial milestone payments [1] - The transaction is expected to be completed in the first half of 2026 [1] Group 2: Financial Implications for Via Biotech - Via Biotech anticipates receiving up to approximately $40 million in investment returns from this transaction, contingent on subsequent regulatory approvals and the achievement of commercialization milestones [1] - Arthrosi has established a new Statement of Work (SOW) with Via Biotech's CDMO subsidiary, Langhua Pharmaceutical, for the supply of active pharmaceutical ingredients, indicating ongoing business collaboration [1]

Core Viewpoint - Via Biotechnology (01873) shares rose over 13% following the announcement of a significant acquisition deal between Swedish Orphan Biovitrum AB (Sobi) and Arthrosi, in which Via Biotechnology is involved [1] Group 1: Acquisition Details - On December 13, Sobi announced an acquisition agreement with Arthrosi, with a total transaction value of up to $1.5 billion, including an upfront payment of $950 million and up to $550 million in regulatory and commercial milestone payments [1] - The transaction is expected to be completed in the first half of 2026 [1] Group 2: Financial Impact on Via Biotechnology - Via Biotechnology anticipates receiving up to approximately $40 million in investment returns from this transaction, contingent on subsequent regulatory approvals and the achievement of commercialization milestones [1] - Arthrosi has established a new Statement of Work (SOW) with Via Biotechnology's CDMO subsidiary, Langhua Pharmaceutical, for the supply of active pharmaceutical ingredients, indicating ongoing business collaboration [1]

Core Viewpoint - Via Bio (01873.HK) announced that its wholly-owned subsidiary, Via Incubator, holds a minority stake in Arthrosi Therapeutics, which will be accounted for as a financial asset at fair value in the company's consolidated financial statements. Arthrosi Therapeutics has informed the company that Sobi US Holding Corp. has agreed to acquire it through a merger, and post-completion, the company will no longer hold any equity in Arthrosi Therapeutics. The merger agreement includes an upfront payment of $950 million, subject to customary adjustments, and contingent consideration of up to $550 million [1][2]. Group 1 - Via Incubator holds approximately 3.14% of Arthrosi Therapeutics' equity on a fully diluted and converted basis as of the announcement date [2]. - The buyer, Sobi US Holding Corp., is a wholly-owned subsidiary of Swedish Orphan Biovitrum AB, a global biopharmaceutical company focused on innovative treatments for rare diseases [1][2]. - Arthrosi Therapeutics is a clinical-stage biotechnology company developing pozdeutinurad, a potential next-generation URAT1 inhibitor aimed at lowering serum uric acid levels in patients with progressive gout [2].

Group 1 - The core point of the article is that Via Biotechnology (维亚生物) announced the acquisition of Arthrosi Therapeutics by Sobi US Holding Corp, with a total upfront payment of $950 million and potential contingent payments not exceeding $550 million [1][2] - Arthrosi Therapeutics is a clinical-stage biotechnology company focused on the development of pozdeutinurad, a new generation URAT1 inhibitor aimed at lowering serum uric acid levels in patients with progressive gout [1] - As of the announcement date, Via Incubator holds approximately 3.14% of the equity in Arthrosi Therapeutics on a fully diluted and converted basis [1] Group 2 - The board believes that the acquisition allows the group to realize the long-term accumulated investment value in Arthrosi Therapeutics and provides an opportunity to enhance the group's financial flexibility [2] - The group plans to use the proceeds from the acquisition to supplement its working capital and support the growth and development of other investments and incubation businesses [2]

Group 1 - The core announcement is that Via Biotechnology (01873) has been informed by Arthrosi Therapeutics about a planned acquisition by Sobi US Holding Corp, set to be completed by December 13, 2025 [1] - The acquisition agreement includes an upfront payment of $950 million, subject to customary adjustments, and potential contingent payments not exceeding $550 million [1] - Via Biotechnology currently holds approximately 3.14% of Arthrosi Therapeutics' equity, calculated on a fully diluted and converted basis [1] Group 2 - The board believes that the acquisition will allow the company to realize the long-term investment value accumulated in Arthrosi Therapeutics since its investment [2] - The proceeds from the acquisition are intended to supplement the company's working capital and support the growth and development of other investments and incubation businesses [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全 部 或 任 何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 （於開曼群島註冊成立的獲豁免有限公司） （股份代號：1873） 須予披露交易 出售於一間投資孵化企業的股權 併 購 維 亞 孵 化 器（本 公 司 全 資 附 屬 公 司）持 有Arthrosi Therapeutics股 本 中 的 少 數 股 權， 有關股權於本公司的綜合財務報表內以按公平值列入損益的金融資產入賬。 董 事 會 欣 然 宣 佈，Arthrosi Therapeutics已 知 會 本 公 司，於 二 零 二 五 年 十 二 月 十 三 日，買方已同意透過併購方式收購Arthrosi Therapeutics。緊隨完成後，本公司將不 再持有Arthrosi Therapeutics的 任 何 股 權。併 購 協 議 當 中 規 定 於 完 成 時 支 付 的 預 付 款 為950百 萬 美 元（可 作 出 慣 常 調 整）及 ...

Core Viewpoint - Via Biotechnology (01873) announced the granting of stock options to several qualified participants, allowing the subscription of a total of 8.58 million ordinary shares, based on its stock option plan adopted on April 14, 2019 [1] Summary by Relevant Categories - **Company Announcement** - The company will grant stock options on December 2, 2025, under its stock option plan [1] - A total of 8.58 million ordinary shares will be available for subscription [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全 部 或 任 何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 （於開曼群島註冊成立的獲豁免有限公司） （股份代號：1873） 授出購股權 本公告由 維 亞 生物科技控股 集 團（「本公司」，連 同 其 附 屬 公 司 統 稱「本集團」）根 據 香 港 聯 合 交 易 所 有 限 公 司（「聯交所」）證 券 上 市 規 則（「上市規則」）第17.06A條作出。 本 公 司 董 事（「董 事」）會（「董事會」）宣 佈，本 公 司 根 據 其 於 二 零 一 九 年 四 月 十 四 日 採 納 的 購 股 權 計 劃（「首次公開發售後購股權計劃」）於 二 零 二 五 年 十 二 月 二 日 向 若 干 合資格參與者授出購股權（「購股權」），以認購本公司合共8,580,000股普通股（「股份」）。 已授出之購股權之詳情載列如下： 授出日期： 二 零 二 五 年 十 二 月 二 日（「授出日期」） – 1 – 購 ...